-
1 Comment
Ascletis Pharma Inc is currently in a long term uptrend where the price is trading 19.8% above its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 18.7.
Finally, its free cash flow fell by 590.5% to $-34M since the same quarter in the previous year.
Based on the above factors, Ascletis Pharma Inc gets an overall score of 2/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| ISIN | KYG0520K1094 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Beta | None |
|---|---|
| Market Cap | 537M |
| PE Ratio | None |
| Target Price | None |
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 2VJ.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
